Pleomorphic LCIS what do we know?: A UK multicenter audit of pleomorphic lobular carcinoma in situ

Yazan A Masannat; Ehab Husain; Rebecca Roylance; Steven D Heys; Pauline J Carder; Hiam Ali; Yasmine Maurice; Sarah E Pinder; Elinor Sawyer; Abeer M Shaaban

doi:10.1016/j.breast.2017.12.011

Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ

Yazan A Masannat, Ehab Husain, Rebecca Roylance, Steven D Heys, Pauline J Carder, Hiam Ali, Yasmine Maurice, Sarah E Pinder, Elinor Sawyer, Abeer M Shaaban

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

AIMS: Pleomorphic lobular carcinoma in situ (PLCIS) is a relatively newly described pathological lesion that is distinguished from classical LCIS by its large pleomorphic nuclei. The lesion is uncommon and its appropriate management has been debated. The aim of this study is to review data from a large series of PLCIS to examine its natural history in order to guide management plans.

MATERIALS AND METHODS: Comprehensive pathology data were collected from two cohorts; one from a UK multicentre audit and the other a series of PLCIS cases identified from within the GLACIER study cohort. 179 cases were identified of whom 176 had enough data for analysis.

RESULTS: Out of these 176 cases, 130 had invasive disease associated with PLCIS, the majority being of lobular type (classical and/or pleomorphic). A high incidence of histological grade 2 and 3 invasive cancers was noted with a predominance of ER positive and HER-2 negative malignancy. When PLCIS was the most significant finding on diagnostic biopsy the upgrade to invasive disease on excision was 31.8%, which is higher than pooled data for classical LCIS and DCIS.

CONCLUSION: The older age at presentation, high grade of upgrade to invasive cancer, common association with higher grade tumours suggest that PLCIS is an aggressive form of insitu disease. These findings support the view that PLCIS is a more aggressive form of lobular in situ neoplasia and supports the tendency to treat akin to DCIS.

Original language	English
Pages (from-to)	120-124
Number of pages	5
Journal	Breast
Volume	38
Early online date	5 Jan 2018
DOIs	https://doi.org/10.1016/j.breast.2017.12.011
Publication status	Published - 30 Apr 2018

Bibliographical note

Conflict of interest: No Conflict of interest: All authors don't have any financial or personal relationships with other people or organisations that could inappropriately influence (bias) their work.

Keywords

Breast cancer
Lobular cancer in situ
Pleomorphic lobular carcinoma in situ

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breast.2017.12.011Licence: Unspecified

Cite this

@article{b77306afb00f4690afd067033c45d17b,

title = "Pleomorphic LCIS what do we know?: A UK multicenter audit of pleomorphic lobular carcinoma in situ",

abstract = "AIMS: Pleomorphic lobular carcinoma in situ (PLCIS) is a relatively newly described pathological lesion that is distinguished from classical LCIS by its large pleomorphic nuclei. The lesion is uncommon and its appropriate management has been debated. The aim of this study is to review data from a large series of PLCIS to examine its natural history in order to guide management plans.MATERIALS AND METHODS: Comprehensive pathology data were collected from two cohorts; one from a UK multicentre audit and the other a series of PLCIS cases identified from within the GLACIER study cohort. 179 cases were identified of whom 176 had enough data for analysis.RESULTS: Out of these 176 cases, 130 had invasive disease associated with PLCIS, the majority being of lobular type (classical and/or pleomorphic). A high incidence of histological grade 2 and 3 invasive cancers was noted with a predominance of ER positive and HER-2 negative malignancy. When PLCIS was the most significant finding on diagnostic biopsy the upgrade to invasive disease on excision was 31.8%, which is higher than pooled data for classical LCIS and DCIS.CONCLUSION: The older age at presentation, high grade of upgrade to invasive cancer, common association with higher grade tumours suggest that PLCIS is an aggressive form of insitu disease. These findings support the view that PLCIS is a more aggressive form of lobular in situ neoplasia and supports the tendency to treat akin to DCIS.",

keywords = "Breast cancer, Lobular cancer in situ, Pleomorphic lobular carcinoma in situ",

author = "Masannat, {Yazan A} and Ehab Husain and Rebecca Roylance and Heys, {Steven D} and Carder, {Pauline J} and Hiam Ali and Yasmine Maurice and Pinder, {Sarah E} and Elinor Sawyer and Shaaban, {Abeer M}",

note = "Conflict of interest: No Conflict of interest: All authors don't have any financial or personal relationships with other people or organisations that could inappropriately influence (bias) their work.",

year = "2018",

month = apr,

day = "30",

doi = "10.1016/j.breast.2017.12.011",

language = "English",

volume = "38",

pages = "120--124",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Pleomorphic LCIS what do we know?

T2 - A UK multicenter audit of pleomorphic lobular carcinoma in situ

AU - Masannat, Yazan A

AU - Husain, Ehab

AU - Roylance, Rebecca

AU - Heys, Steven D

AU - Carder, Pauline J

AU - Ali, Hiam

AU - Maurice, Yasmine

AU - Pinder, Sarah E

AU - Sawyer, Elinor

AU - Shaaban, Abeer M

N1 - Conflict of interest: No Conflict of interest: All authors don't have any financial or personal relationships with other people or organisations that could inappropriately influence (bias) their work.

PY - 2018/4/30

Y1 - 2018/4/30

N2 - AIMS: Pleomorphic lobular carcinoma in situ (PLCIS) is a relatively newly described pathological lesion that is distinguished from classical LCIS by its large pleomorphic nuclei. The lesion is uncommon and its appropriate management has been debated. The aim of this study is to review data from a large series of PLCIS to examine its natural history in order to guide management plans.MATERIALS AND METHODS: Comprehensive pathology data were collected from two cohorts; one from a UK multicentre audit and the other a series of PLCIS cases identified from within the GLACIER study cohort. 179 cases were identified of whom 176 had enough data for analysis.RESULTS: Out of these 176 cases, 130 had invasive disease associated with PLCIS, the majority being of lobular type (classical and/or pleomorphic). A high incidence of histological grade 2 and 3 invasive cancers was noted with a predominance of ER positive and HER-2 negative malignancy. When PLCIS was the most significant finding on diagnostic biopsy the upgrade to invasive disease on excision was 31.8%, which is higher than pooled data for classical LCIS and DCIS.CONCLUSION: The older age at presentation, high grade of upgrade to invasive cancer, common association with higher grade tumours suggest that PLCIS is an aggressive form of insitu disease. These findings support the view that PLCIS is a more aggressive form of lobular in situ neoplasia and supports the tendency to treat akin to DCIS.

AB - AIMS: Pleomorphic lobular carcinoma in situ (PLCIS) is a relatively newly described pathological lesion that is distinguished from classical LCIS by its large pleomorphic nuclei. The lesion is uncommon and its appropriate management has been debated. The aim of this study is to review data from a large series of PLCIS to examine its natural history in order to guide management plans.MATERIALS AND METHODS: Comprehensive pathology data were collected from two cohorts; one from a UK multicentre audit and the other a series of PLCIS cases identified from within the GLACIER study cohort. 179 cases were identified of whom 176 had enough data for analysis.RESULTS: Out of these 176 cases, 130 had invasive disease associated with PLCIS, the majority being of lobular type (classical and/or pleomorphic). A high incidence of histological grade 2 and 3 invasive cancers was noted with a predominance of ER positive and HER-2 negative malignancy. When PLCIS was the most significant finding on diagnostic biopsy the upgrade to invasive disease on excision was 31.8%, which is higher than pooled data for classical LCIS and DCIS.CONCLUSION: The older age at presentation, high grade of upgrade to invasive cancer, common association with higher grade tumours suggest that PLCIS is an aggressive form of insitu disease. These findings support the view that PLCIS is a more aggressive form of lobular in situ neoplasia and supports the tendency to treat akin to DCIS.

KW - Breast cancer

KW - Lobular cancer in situ

KW - Pleomorphic lobular carcinoma in situ

U2 - 10.1016/j.breast.2017.12.011

DO - 10.1016/j.breast.2017.12.011

M3 - Article

C2 - 29310036

SN - 0960-9776

VL - 38

SP - 120

EP - 124

JO - Breast

JF - Breast

ER -